Scandinavian ChemoTech AB Series B (CMOTEC-B) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Scandinavian ChemoTech AB Series B (CMOTEC-B) has a cash flow conversion efficiency ratio of -0.698x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-1.14 Million ≈ $-123.01K USD) by net assets (Skr1.64 Million ≈ $176.17K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CMOTEC-B net asset quality score to measure how much of total assets are equity-financed.
Scandinavian ChemoTech AB Series B - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Scandinavian ChemoTech AB Series B's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how aggressively does Scandinavian ChemoTech AB Series B reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Scandinavian ChemoTech AB Series B Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scandinavian ChemoTech AB Series B ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aston Bay Holdings Ltd
V:BAY
|
-0.716x |
|
Nictus
JSE:NCS
|
1.035x |
|
Duketon Mining Ltd
AU:DKM
|
-0.008x |
|
Xref Ltd
AU:XF1
|
0.137x |
|
Nyrstar NV
BR:NYR
|
0.000x |
|
Brunner Investment Trust
LSE:BUT
|
0.004x |
|
Turnstone Biologics Corp. Common Stock
NASDAQ:TSBX
|
-0.292x |
|
Langgeng Makmur Industri Tbk
JK:LMPI
|
-0.229x |
Annual Cash Flow Conversion Efficiency for Scandinavian ChemoTech AB Series B (2014–2025)
The table below shows the annual cash flow conversion efficiency of Scandinavian ChemoTech AB Series B from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see Scandinavian ChemoTech AB Series B market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr3.19 Million ≈ $342.86K |
Skr-3.75 Million ≈ $-403.02K |
-1.175x | +46.53% |
| 2024-12-31 | Skr5.98 Million ≈ $643.54K |
Skr-13.14 Million ≈ $-1.41 Million |
-2.198x | -33.04% |
| 2023-12-31 | Skr11.03 Million ≈ $1.19 Million |
Skr-18.23 Million ≈ $-1.96 Million |
-1.652x | -17.77% |
| 2022-12-31 | Skr13.99 Million ≈ $1.51 Million |
Skr-19.63 Million ≈ $-2.11 Million |
-1.403x | -74.92% |
| 2021-12-31 | Skr23.92 Million ≈ $2.57 Million |
Skr-19.18 Million ≈ $-2.06 Million |
-0.802x | +12.79% |
| 2020-12-31 | Skr9.24 Million ≈ $993.94K |
Skr-8.49 Million ≈ $-914.09K |
-0.920x | +20.30% |
| 2019-12-31 | Skr9.73 Million ≈ $1.05 Million |
Skr-11.23 Million ≈ $-1.21 Million |
-1.154x | -416.46% |
| 2018-12-31 | Skr20.50 Million ≈ $2.21 Million |
Skr-4.58 Million ≈ $-492.77K |
-0.223x | +84.65% |
| 2017-12-31 | Skr10.29 Million ≈ $1.11 Million |
Skr-14.97 Million ≈ $-1.61 Million |
-1.456x | -182.40% |
| 2016-12-31 | Skr14.58 Million ≈ $1.57 Million |
Skr-7.52 Million ≈ $-808.93K |
-0.515x | +5.74% |
| 2015-12-31 | Skr868.64K ≈ $93.48K |
Skr-474.99K ≈ $-51.12K |
-0.547x | +38.15% |
| 2014-12-31 | Skr46.27K ≈ $4.98K |
Skr-40.91K ≈ $-4.40K |
-0.884x | -- |
About Scandinavian ChemoTech AB Series B
Scandinavian ChemoTech AB (publ), a medical technology company, engages in the radiation physics, surgical oncology, and clinical development in Sweden and internationally. It operates in two divisions, Human Care and Animal Care. The company offers IQWave, an electroporation that generates a tumour-specific electrical stimulation; and veterinary medicines under the vetIQur name. Scandinavian Che… Read more